Increasing the validity of experimental models for depression

Annals of the New York Academy of Sciences

Volumn 1265, Issue 1, 2012, Pages 36-45

  Dzirasa, Kafui ^a   Covington, Herbert E ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Endophenotypes, models; Major depressive disorder; Mouse

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY; ARTICLE; DISEASE MODEL; ENDOPHENOTYPE; EXPERIMENTAL TEST; FORCED SWIMMING TEST; HUMAN; IN VIVO STUDY; MAJOR DEPRESSION; NEUROPHYSIOLOGY; NONHUMAN; SOCIAL STRESS; TAIL SUSPENSION TEST;

EID: 84865104079     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06669.x     Document Type: Article

References (78)

1. Akil, H. et al 2010. Medicine. The future of psychiatric research: genomes and neural circuits. Science 327: 1580-1581.
2. APA. 2000. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. American Psychiatric Association. Washington, D.C
3. Blazer, D.G. et al 1994. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am. J. Psychiatry 151: 979-986.
4. Kessler, R.C. et al 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry 51: 8-19.
5. Mathers, C.D. & D. Loncar 2006. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3: e442.
6. Drevets, W.C. 2001. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr. Opin. Neurobiol. 11: 240-249.
7. Liotti, M. & H.S. Mayberg 2001. The role of functional neuroimaging in the neuropsychology of depression. J. Clin. Exp. Neuropsychol. 23: 121-136.
8. Jacobsen, J.P. et al 2012. Deficient serotonin neurotransmission and depression-like serotonin biomarker alterations in tryptophan hydroxylase 2 (Tph2) loss-of-function mice. Mol Psychiatry 17: 694-704.
9. Nestler, E.J. & S.E. Hyman 2010. Animal models of neuropsychiatric disorders. Nat. Neurosci. 13: 1161-1169.
10. Gordon, J.A. 2010. Testing the glutamate hypothesis of schizophrenia. Nat. Neurosci. 13: 2-4.
11. Cryan, J.F., A. Markou & I. Lucki 2002. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 23: 238-245.
12. Dandy, K.L. & M.B. Gatch 2009. The effects of chronic cocaine exposure on impulsivity in rats. Behav. Pharmacol. 20: 400-405.
13. Reith, M.E., M. Benuck & A. Lajtha 1987. Cocaine disposition in the brain after continuous or intermittent treatment and locomotor stimulation in mice. J. Pharmacol. Exp. Ther. 243: 281-287.
14. Geyer, M.A. 1998. Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Pharmacopsychiatry 31(Suppl 2): 73-79.
15. Covington, H.E., 3rd, V. Vialou & E.J. Nestler 2010. From synapse to nucleus: novel targets for treating depression. Neuropharmacology 58: 683-693.
16. Hasler, G. et al 2004. Discovering endophenotypes for major depression. Neuropsychopharmacology 29: 1765-1781.
17. Berton, O. & E.J. Nestler 2006. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 7: 137-151.
18. Lekman, M., S. Paddock & F.J. McMahon 2008. Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Mol. Diagn. Ther. 12: 321-330.
19. Monteggia, L.M. et al 2007. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol. Psychiatry 61: 187-197.
20. Krishnan, V. & E.J. Nestler 2010. Linking molecules to mood: new insight into the biology of depression. Am. J. Psychiatry 167: 1305-1320.
21. Nestler, E.J. et al 2002. Neurobiology of depression. Neuron 34: 13-25.
22. Krishnan, V. & E.J. Nestler 2008. The molecular neurobiology of depression. Nature 455: 894-902.
23. Fava, M. & K.S. Kendler 2000. Major depressive disorder. Neuron 28: 335-341.
24. Selye, H. 1950. Stress and the general adaptation syndrome. Br. Med. J. 1: 1383-1392.
25. McEwen, B.S. 1998. Stress, adaptation, and disease. Allostasis and allostatic load. Ann. N.Y. Acad. Sci. 840: 33-44.
26. Willner, P., R. Muscat & M. Papp 1992. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci. Biobehav. Rev. 16: 525-534.
27. Willner, P. 1984. The validity of animal models of depression. Psychopharmacology 83: 1-16.
28. Krishnan, V. et al 2007. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131: 391-404.
29. Dias-Ferreira, E. et al 2009. Chronic stress causes frontostriatal reorganization and affects decision-making. Science 325: 621-625.
30. Radley, J.J. et al 2008. Repeated stress alters dendritic spine morphology in the rat medial prefrontal cortex. J. Comp. Neurol. 507: 1141-1150.
31. Czeh, B. et al 2007. Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment. Neuropsychopharmacology 32: 1490-1503.
32. Liston, C. et al 2006. Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. J. Neurosci. 26: 7870-7874.
33. Miczek, K.A. et al 2004. Aggression and defeat: persistent effects on cocaine self-administration and gene expression in peptidergic and aminergic mesocorticolimbic circuits. Neurosci. Biobehav. Rev. 27: 787-802.
34. Nikulina, E.M. et al 2004. Long-term behavioral and neuronal cross-sensitization to amphetamine induced by repeated brief social defeat stress: Fos in the ventral tegmental area and amygdala. Neuroscience 123: 857-865.
35. Miczek, K.A., J.J. Yap & H.E. Covington, 3rd. 2008. Social stress, therapeutics and drug abuse: preclinical models of escalated and depressed intake. Pharmacol. Ther. 120: 102-128.
36. Cruz, F.C. et al 2008. Maternal separation stress in male mice: long-term increases in alcohol intake. Psychopharmacology 201: 459-468.
37. Hyson, R.L. et al 1982. Extent and control of shock affects naltrexone sensitivity of stress-induced analgesia and reactivity to morphine. Pharmacol. Biochem. Behav. 17: 1019-1025.
38. Maier, S.F., R.C. Drugan & J.W. Grau 1982. Controllability, coping behavior, and stress-induced analgesia in the rat. Pain 12: 47-56.
39. Weiss, J.M. 1972. Psychological factors in stress and disease. Sci. Am. 226: 104-113.
40. Weiss, J.M. 1972. Influence of psychological variables on stress-induced pathology. Ciba Found. Symp. 8: 253-265.
41. Berton, O. et al 2006. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311: 864-868.
42. Crawley, J.N. 2007. What's Wrong with My Mouse?: Behavioral Phenotyping of Transgenic and Knockout Mice. John Wiley & Sons. Hoboken, NJ
43. Maier, S.F. 1984. Learned helplessness and animal models of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 8: 435-446.
44. Seligman, M.E. 1972. Learned helplessness. Annu. Rev. Med. 23: 407-412.
45. Spielewoy, C. et al 2000. Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behav. Pharmacol. 11: 279-290.
46. Brocco, M. et al 2002. Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents. Pharmacol. Biochem. Behav. 71: 667-680.
47. Azrin, N.H., J. Hopwood & J. Powell 1967. A rat chamber and electrode procedure for avoidance conditioning. J. Exp. Anal. Behav. 10: 291-298.
48. Fukui, M. et al 2007. Vmat2 heterozygous mutant mice display a depressive-like phenotype. J. Neurosci. 27: 10520-10529.
49. Crawley, J.N. 1985. Exploratory behavior models of anxiety in mice. Neurosci. Biobehav. Rev. 9: 37-44.
50. Walsh, R.N. & R.A. Cummins 1976. The open-field test: a critical review. Psychol. Bull. 83: 482-504.
51. Kranz, G.S., S. Kasper & R. Lanzenberger 2010. Reward and the serotonergic system. Neuroscience 166: 1023-1035.
52. Bevins, R.A. & J. Besheer 2005. Novelty reward as a measure of anhedonia. Neurosci. Biobehav. Rev. 29: 707-714.
53. Strekalova, T. et al 2011. Update in the methodology of the chronic stress paradigm: internal control matters. Behav. Brain Funct. 7: 9.
54. Markou, A. & G.F. Koob 1991. Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology 4: 17-26.
55. Knoll, A.T. & W.A. Carlezon, Jr. 2010. Dynorphin, stress, and depression. Brain Res. 1314: 56-73.
56. Fish, E.W. et al 2010. Alcohol, cocaine, and brain stimulation-reward in C57Bl6/J and DBA2/J mice. Alcohol Clin. Exp. Res. 34: 81-89.
57. Carlezon, W.A., Jr. & E.H. Chartoff 2007. Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat. Protoc. 2: 2987-2995.
58. Tsai, H.C. et al 2009. Phasic firing in dopaminergic neurons is sufficient for behavioral conditioning. Science 324: 1080-1084.
59. Fawcett, J. et al 1983. Differences between anhedonic and normally hedonic depressive states. Am. J. Psychiatry 140: 1027-1030.
60. Barrot, M. et al 2005. Regulation of anxiety and initiation of sexual behavior by CREB in the nucleus accumbens. Proc. Natl. Acad. Sci. USA 102: 8357-8362.
61. Schober, J., Z. Weil & D. Pfaff 2011. How generalized CNS arousal strengthens sexual arousal (and vice versa). Horm. Behav. 59: 689-695.
62. Robbins, T.W. 2002. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology 163: 362-380.
63. Dzirasa, K. et al 2006. Dopaminergic control of sleep-wake states. J. Neurosci. 26: 10577-10589.
64. Dzirasa, K. 2008. Chronic recordings in transgenic mice. In Methods for Neural Ensemble Recordings. Nicolelis, M.A., ed.: 83-96. CRC Press. Boca Raton, FL.
65. Naylor, E. et al 2000. The circadian clock mutation alters sleep homeostasis in the mouse. J. Neurosci. 20: 8138-8143.
66. Angst, J. & A. Dobler-Mikola 1985. The Zurich Study: VI. A continuum from depression to anxiety disorders? Eur. Arch. Psychiatry Neurol. Sci. 235: 179-186.
67. Merikangas, K.R. et al 2003. Longitudinal trajectories of depression and anxiety in a prospective community study: the Zurich Cohort Study. Arch. Gen. Psychiatry 60: 993-1000.
68. Gawin, F.H. 1991. Cocaine addiction: psychology and neurophysiology. Science 251: 1580-1586.
69. Covington, H.E., 3rd & K.A. Miczek 2003. Vocalizations during withdrawal from opiates and cocaine: possible expressions of affective distress. Eur. J. Pharmacol. 467: 1-13.
70. Burgdorf, J., J. Panksepp & J.R. Moskal 2011. Frequency-modulated 50 kHz ultrasonic vocalizations: a tool for uncovering the molecular substrates of positive affect. Neurosci. Biobehav. Rev. 35: 1831-1836.
71. Covington, H.E., 3rd et al 2010. Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. J. Neurosci. 30: 16082-16090.
72. Lesch, K.P. 1991. 5-HT1A receptor responsivity in anxiety disorders and depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 15: 723-733.
73. Cowen, P.J. et al 1994. 5-HT1A receptor sensitivity in major depression. A neuroendocrine study with buspirone. Br. J. Psychiatry 164: 372-379.
74. Pandey, G.N. et al 2002. Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. Am. J. Psychiatry 159: 419-429.
75. Drevets, W.C., J.L. Price & M.L. Furey 2008. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct. Funct. 213: 93-118.
76. Sheline, Y.I. et al 2010. Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proc. Natl. Acad. Sci. USA 107: 11020-11025.
77. Dzirasa, K. et al 2011. Chronic in vivo multi-circuit neurophysiological recordings in mice. J. Neurosci. Methods 195: 36-46.
78. Hasler, G. & G. Northoff 2011. Discovering imaging endophenotypes for major depression. Mol. Psychiatry 16: 604-619.